Cardlytics, Inc. (NASDAQ:CDLX) Director Scott D. Grimes Sells 2,000 Shares

Cardlytics, Inc. (NASDAQ:CDLX) Director Scott D. Grimes sold 2,000 shares of the business’s stock in a transaction on Thursday, September 16th. The stock was sold at an average price of $91.52, for a total transaction of $183,040.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Scott D. Grimes also recently made the following trade(s):

  • On Monday, August 16th, Scott D. Grimes sold 2,000 shares of Cardlytics stock. The stock was sold at an average price of $78.29, for a total transaction of $156,580.00.

NASDAQ CDLX opened at $93.23 on Thursday. The stock has a market cap of $3.08 billion, a P/E ratio of -30.27 and a beta of 2.54. The company’s 50-day simple moving average is $98.76 and its 200 day simple moving average is $109.86. Cardlytics, Inc. has a twelve month low of $63.15 and a twelve month high of $161.47. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.35.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Tuesday, August 3rd. The company reported ($0.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.19). The business had revenue of $58.85 million during the quarter, compared to the consensus estimate of $63.23 million. Cardlytics had a negative net margin of 41.88% and a negative return on equity of 15.50%. Research analysts anticipate that Cardlytics, Inc. will post -2.77 earnings per share for the current year.

CDLX has been the topic of several research reports. Zacks Investment Research boosted their price objective on shares of Cardlytics to $105.00 in a report on Monday, August 30th. Needham & Company LLC dropped their price objective on shares of Cardlytics from $135.00 to $120.00 and set a “buy” rating on the stock in a report on Wednesday, August 4th. Craig Hallum dropped their price objective on shares of Cardlytics from $160.00 to $120.00 and set a “buy” rating on the stock in a report on Wednesday, August 4th. Finally, TheStreet downgraded shares of Cardlytics from a “c-” rating to a “d+” rating in a report on Wednesday, August 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Cardlytics presently has an average rating of “Hold” and an average target price of $129.00.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. US Bancorp DE increased its stake in Cardlytics by 245.7% in the second quarter. US Bancorp DE now owns 242 shares of the company’s stock valued at $31,000 after acquiring an additional 172 shares during the period. Maverick Capital Ltd. acquired a new position in Cardlytics in the first quarter valued at about $42,000. Sandy Spring Bank acquired a new position in Cardlytics in the second quarter valued at about $63,000. Point72 Hong Kong Ltd boosted its position in Cardlytics by 1,616.3% in the first quarter. Point72 Hong Kong Ltd now owns 738 shares of the company’s stock valued at $81,000 after buying an additional 695 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC boosted its position in Cardlytics by 130.1% in the first quarter. O Shaughnessy Asset Management LLC now owns 856 shares of the company’s stock valued at $94,000 after buying an additional 484 shares in the last quarter. 94.51% of the stock is currently owned by institutional investors and hedge funds.

About Cardlytics

Cardlytics, Inc engages in the development of marketing solutions through its purchase intelligence platform. It operates through the Cardlytics Direct and Other Platform Solutions segments. The Cardlytics Direct segment represents its proprietary native bank advertising channel. The Other Platform Solutions segment includes solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel.

See Also: Dividend Aristocrat Index

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.